Skip to main content

Table 6 Agreement and association between gold standard and PET/CT scan readers

From: 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer

  

Result

Gold standard

X2

P

Kappa

 + ve

− ve

Total No

Primary site

Read. 1

 + ve

34 (100%)

1 (2.2%)

35 (44.3%)

   
  

− ve

0 (0.0%)

44 (97.8%)

44 (55.7%)

67.32

0.00**

0.92

 

Read. 2

 + ve

33 (97.1%)

1 (2.2%)

34 (43%)

   
  

− ve

1 (2.9%)

44 (97.8%)

45 (57%)

71.29

0.00**

0.94

LNs mets

Read. 1

 + ve

43 (79.6%)

4 (16%)

47 (59.5%)

   
  

− ve

11 (20.4%)

21 (84%)

32 (40.5%)

38.95

0.00**

0.701

 

Read. 2

 + ve

40 (74.1%)

5 (20%)

45 (57%)

   
  

− ve

14 (25.9%)

20 (80%)

34 (43%)

34.13

0.00**

0.65

Liver mets

Read. 1

 + ve

46 (93.9%)

5 (16.7%)

51 (64.6%)

   
  

− ve

3 (6.1%)

25 (82.3%)

28 (35.4%)

59.35

0.00**

0.86

 

Read. 2

 + ve

44 (90.0%)

4 (13.3%)

48 (60.8%)

   
  

− ve

5 (10%)

26 (86.7%)

31 (39.2%)

62.93

0.00**

0.89

Peritonial mets

Read. 1

 + ve

23 (82.1%)

1 (1.9%)

24 (30.4%)

   
  

− ve

5 (17.9%)

50 (98.1%)

55 (69.6%)

58.55

0.00**

0.86

 

Read. 2

 + ve

24 (85.7%)

3 (5.9%)

27 (34.2%)

   
  

− ve

4 (14.3%)

48 (94.1%)

52 (65.8%)

66.38

0.00**

0.91

Lung mets

Read. 1

 + ve

22 (78.6%)

3 (5.9%)

25 (31.6%)

   
  

− ve

6 (21.4%)

48 (94.1%)

54 (68.4%)

41.34

0.00**

0.72

 

Read. 2

 + ve

24 (85.7%)

4 (7.8%)

28 (35.4%)

   
  

− ve

4 (24.3%)

47 (92.2%)

51 (64.6%)

42.82

0.00**

0.73

Bone mets

Read. 1

 + ve

12 (85.7%)

1 (1.5%)

13 (16.5%)

   
  

-ve

2 (14.3%)

64 (98.5%)

66 (83.5%)

72.24

0.00**

0.95

 

Read. 2

 + ve

13 (92.9%)

2 (3.1%)

15 (18.9%)

   
  

− ve

1 (7.1%)

63 (96.9%)

64 (81.1%)

59.36

0.00**

0.86

Spleen mets

Read. 1

 + ve

2 (100%)

0 (0.0%)

2 (2.5%)

   
  

− ve

0 (0.0%)

77 (100%)

77 (97.5%)

79.0

0.00**

1.0

 

Read. 2

 + ve

2 (100%)

0 (0.0%)

2 (2.5%)

   
  

− ve

0 (0.0%)

77 (100%)

77 (97.5%)

79.0

0.00**

1.0